Dataset Information
Metabolomic profiling of colon tissue in loperamide-induced constipation mice treated with Rothia mucilaginosa
Ontology highlight
ABSTRACT: Untargeted metabolomics was performed on colon tissue from 26 C57BL/6 mice to investigate metabolic mechanisms underlying Rothia mucilaginosa-mediated constipation alleviation. Mice were divided into normal control (NC, n=8), loperamide-induced constipation model control (MC, n=8), and R. mucilaginosa gavage-treated (RG, n=10) groups. The experimental protocol consisted of adaptation (days 0-7), loperamide modeling (days 8-21), and R. mucilaginosa intervention (days 22-40, BNCC363031, 2x10^8 CFU/day). Colon tissue metabolomics was performed using UHPLC-MS/MS (Vanquish UHPLC coupled with Orbitrap Exploris 120, Thermo Fisher) in both positive and negative ionization modes. This dataset supports the identification of differential metabolites and metabolic pathways associated with R. mucilaginosa intervention in constipation, with particular focus on tryptophan metabolism, bile acid metabolism, and neuroactive signaling.
INSTRUMENT(S): Liquid Chromatography MS - alternating - reverse-phase
PROVIDER: MTBLS13907 | MetaboLights | 2026-04-27
REPOSITORIES: MetaboLights
Dataset's files
Items per page: 1 - 4 of 4 |
Publications
Rothia mucilaginosa alleviates constipation through gut microbiota remodeling and neuroactive pathway activation.
BMC microbiology 20260518 1
<h4>Background</h4>Constipation affects approximately 15% of the global population, and gut microbiota dysbiosis is implicated in its pathogenesis. Rothia mucilaginosa, a commensal bacterium with established anti-inflammatory properties in the respiratory tract, has not been investigated for its effects on intestinal function. This study aimed to evaluate the therapeutic potential of Rothia mucilaginosa in a constipation mouse model using multiomics approaches.<h4>Methods</h4>Loperamide-induced ...[more]
